DANAHER CORP (DHR)       263.79  -6.06 (-2.25%)

263.79  -6.06 (-2.25%)

US2358511028 - Common Stock


Fundamental Rating

4

Taking everything into account, DHR scores 4 out of 10 in our fundamental rating. DHR was compared to 66 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of DHR get a neutral evaluation. Nothing too spectacular is happening here. DHR is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

4

DHR has a Profit Margin of 22.57%. This is better than the industry average of 16.49%.
The Piotroski-F score of DHR is 7.00. This is a strong score and indicates good health and profitability for DHR.

DHR's Return On Assets of 8.42% is in line with the rest of the industry. The industry average Return On Assets is 8.42%.
DHR's Return On Equity of 14.18% is worse than the rest of the industry. The industry average Return On Equity is 16.61%.
VS Industry

ROA (8.42%) VS Industry: 52% outperformed.

0.30
57.39

ROE (14.18%) VS Industry: 36% outperformed.

1.18
180.91

Profit Margin (22.57%) VS Industry: 78% outperformed.

0.20
383.95

Valuation

Valuation Rating

3

With a Price/Earnings Ratio of 24.09, DHR is valued on the expensive side.
Compared to an average industry Price/Earning Ratio of 28.56, DHR is valued in line with its industry peers.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
With a price book ratio of 3.83, DHR is valued correctly.

When comparing the Enterprise Value to EBITDA ratio of DHR to the average industry ratio of 20.72, DHR is valued in line with its industry peers.
With a Forward Price/Earnings Ratio of 25.03, DHR is valued very expensively.
When comparing the price book ratio of DHR to the average industry price book ratio of 2.61, DHR is valued more expensive than its industry peers.
VS Industry

Price/Earnings (24.09) VS Industry: 57% outperformed.

122.09
7.53

Price/Book (3.83) VS Industry: 37% outperformed.

52.24
0.33

Enterprise Value/ EBITDA (19.26) VS Industry: 60% outperformed.

746.65
2.30

Growth

Growth Rating

4

DHR shows a strong growth in Earnings Per Share. Measured over the last 5 years, the EPS has been growing by 22.13% yearly.
DHR shows quite a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 15.19% yearly.
DHR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 8.85%.
DHR is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 8.60% yearly.

Looking at the last year, DHR shows a small growth in Revenue. The Revenue has grown by 6.85% in the last year.
DHR is expected to show a small growth in Revenue. In the coming 5 years, the Revenue will grow by 5.95% yearly.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS22.13% 32.57% 8.85% -3.77% 2.85% 5.28% 8.6%
Revenue15.19% 20.67% 6.85% -0.07% 3.83% 5.18% 5.95%

Health

Health Rating

5

An Altman-Z score of 4.91 indicates that DHR is not in any danger for bankruptcy at the moment.
The Altman-Z score of DHR is much better than the industry average of 2.40.
The Piotroski-F score of DHR is 7.00. This is a strong score and indicates good health and profitability for DHR.
DHR has a Current Ratio of 1.89. This is a normal value and indicates that DHR is financially healthy and should not expect problems in meeting its short term obligations.

A Quick Ratio of 1.52 indicates that DHR should not have too much problems paying its short term obligations.
Compared to an average industry Current Ratio of 4.77, DHR is worse placed to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of DHR to the average industry Current Ratio of 4.30, DHR is less able to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.08, DHR is more dependent on financing than its industry peers.
VS Industry

Debt/Equity (0.38) VS Industry: 36% outperformed.

3.88
0.00

Quick Ratio (1.52) VS Industry: 30% outperformed.

0.04
40.60

Current Ratio (1.89) VS Industry: 24% outperformed.

0.04
40.60

Altman-Z (4.91) VS Industry: 66% outperformed.

-152.43
23.82

Dividend

Dividend Rating

5

On average, the dividend of DHR grows each year by 9.32%, which is quite nice.
DHR pays out 11.52% of its income as dividend. This is a sustainable payout ratio.
DHR has been paying a dividend for at least 10 years, so it has a reliable track record.
Compared to an average industry Dividend Yield of 0.36, DHR has a dividend in line with its industry peers.

With a yearly dividend of 0.36%, DHR is not a good candidate for dividend investing.
With a Dividend Yield of 0.36, DHR pays less dividend than the S&P500 average, which is at 2.41.
DHR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
VS Industry

Dividend Yield (0.36%) VS Industry: 57% outperformed.

0.20
0.72

DANAHER CORP263.79

NYSE:DHR (2/6/2023, 1:56:09 PM)-6.06 (-2.25%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Life Sciences Tools & Services
Earnings (Last) 01-24 2023-01-24/bmo Earnings (Next) 04-19 2023-04-19/amc
Inst Owners 77.19% Inst Owner Change -56.25%
Ins Owners 0.47% Ins Owner Change 2.71%
Market Cap 192.03B Analysts 80
Price Target 311.15 (17.95%)

Dividend
Industry RankSector Rank
Dividend Yield 0.36%
Dividend Growth(5Y) 9.32% DP 11.52%
Div Incr Years 5 Div Non Decr Years 5
Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 11.9%
Min EPS beat(2) 11.67% Max EPS beat(2) 12.13%
EPS beat(4) 4 Avg EPS beat(4) 10.69%
Min EPS beat(4) 2.64% Max EPS beat(4) 16.31%
Revenue beat(2) 2 Avg Revenue beat(2) 5.41%
Min Revenue beat(2) 4.84% Max Revenue beat(2) 5.99%
Revenue beat(4) 4 Avg Revenue beat(4) 4.21%
Min Revenue beat(4) 0.91% Max Revenue beat(4) 5.99%
PT rev (1m) -0.39% PT rev (3m) -0.87%
EPS NQ rev (1m) -8.24% EPS NQ rev (3m) -9.74%
EPS NY rev (1m) 0% EPS NY rev (3m) -2.49%
Revenue NQ rev (1m) -3.9% Revenue NQ rev (3m) -4.07%
Revenue NY rev (1m) 0% Revenue NY rev (3m) -0.03%

Valuation
Industry RankSector Rank
PE 24.09
Fwd PE 25.03
P/S 6.1
P/FCF 26.07
P/OCF 22.54
P/B 3.83
P/tB N/A
EV/EBITDA 19.26
EPS(TTM) 10.95 EY 4.15%
EPS(NY) 10.54 Fwd EY 3.99%
FCF(TTM) 10.12 FCFY 3.84%
OCF(TTM) 11.7 OCFY 4.44%
SpS 43.23 BVpS 68.8
TBVpS -13.7 PEG (NY) N/A
PEG (5Y) 1.09

Profitability
Industry RankSector Rank
ROA 8.42%
ROE 14.18%
ROIC 9.75%
ROICexc 10.58%
ROICexgc 74.7%
OM 27.61%
PM 22.57%
GM 60.21%
ROICexgc(3y) 70.02% ROICexcg growth 3Y 8.58%
ROICexcg growth 5Y 8.54% ROICexc(3y) 8.37%
ROICexc growth 3Y 12.25% ROICexc growth 5Y 14.76%
OM growth 3Y 14.79% OM growth 5Y 10.74%
PM growth 3Y 11.2% PM growth 5Y 7.05%
GM growth 3Y 2.6% GM growth 5Y 1.74%
F-Score 7 Asset Turnover 0.37

Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF 2.67
Debt/EBITDA 1.8
Cap/Depr 51.85%
Profit Quality 103.72%
Current Ratio 1.89
Quick Ratio 1.52
Altman-Z 4.91
F-Score 7 WACC 9.73%
ROIC/WACC 7.68 Cap/Depr(3y) 52.03%
Cap/Depr(5y) 51.93% Profit Quality(3y) 123.58%
Profit Quality(5y) 122.1%

Growth
EPS 1Y 8.85% EPS 3Y 32.57%
EPS 5Y 22.13% EPS growth Q2Q 6.69%
EPS Next Y -3.77% EPS Next 2Y 2.85%
EPS Next 3Y 5.28% EPS Next 5Y 8.6%
Revenue growth 1Y 6.85% Revenue growth 3Y 20.67%
Revenue growth 5Y 15.19% Revenue growth Q2Q 2.71%
Revenue Next Year -0.07% Revenue Next 2Y 3.83%
Revenue Next 3Y 5.18% Revenue Next 5Y 5.95%
EBIT growth 1Y 16.38% EBIT growth 3Y 38.52%
EBIT growth 5Y 27.56% EBIT Next Year 9.38%
EBIT Next 3Y 8.98% EBIT Next 5Y 9.22%
FCF growth 1Y 4.29% FCF growth 3Y 30.48%
FCF growth 5Y 20.85% OCF growth 1Y 1.93%
OCF growth 3Y 29.18% OCF growth 5Y 19.62%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA